NMN for slowing aging
Does taking NMN improve any measured health outcome in humans?
The idea, and why it's appealing
NAD+ is a coenzyme every cell uses to run metabolism and DNA repair. Levels of it decline with age. Nicotinamide mononucleotide is a direct precursor — the molecule your body converts into NAD+ — and its availability is a rate-limiting step in that pathway.
So the syllogism writes itself: NAD+ falls with age, NMN raises NAD+, therefore NMN opposes aging. It is a genuinely elegant hypothesis with real rodent data behind it, and it is why NMN became one of the best-selling longevity supplements in the world.
The trials test the middle step. That turns out to matter enormously.
Measuring a different question
A surrogate endpoint is a marker researchers measure because it's fast and cheap, standing in for the outcome anyone actually cares about. Blood NAD+ is a surrogate. Living longer or better is the real endpoint.
Surrogates are legitimate research tools. They become a problem when the surrogate moves, the real endpoint is never measured, and the marketing quietly treats the first as proof of the second.
What the trials measured
- Blood NAD+ concentration
- Fasting glucose and insulin
- Grip strength, gait speed
- Six-minute walking distance
What people buy it for
- Slower biological aging
- More healthy years
- Reduced disease risk
- Longer life
Not one published human trial has measured anything in the right-hand column. That is not a criticism of the researchers — those trials would take decades and enormous funding. It is a description of what is and isn't known.
What the trials found
A 2024 systematic review and meta-analysis pooled eight randomized controlled trials covering 342 participants, mostly middle-aged and older adults without diabetes.1 Five of the eight reported that blood NAD+ rose. The surrogate moved.
Then they looked at whether anything else did.
Pooled outcomes, NMN 250–2,000 mg/day vs. placebo — 8 RCTs, 342 participants
The authors' conclusion is unambiguous: short-term NMN supplementation at 250–2,000 mg/day "did not show significantly positive impacts on glucose control and lipid profile."1
The single near-miss is HOMA-IR, and it deserves scrutiny rather than enthusiasm. It did not reach significance, and the reviewers note it became non-significant entirely when one study was excluded.1 A signal that survives only while one particular trial is included is a hypothesis, not a finding.
A separate 2024 review examined physical performance across ten randomized trials and 437 participants — grip strength, gait speed, six-minute walk, chair-stand, VO₂max, quality of life. Heterogeneity was too high to pool the results at all.2
A lesson in reading titles
That performance review is worth pausing on, because it teaches a habit worth more than anything specific to NMN.
"Nonsignificant improvement" means the study could not distinguish the result from chance. The title states an improvement; the paper reports one it could not confirm. Nothing here is fabricated — but a reader who stops at the title, or a marketer who quotes only the title, walks away with the opposite of what the research found.
This is why we read the papers rather than the abstracts, and the abstracts rather than the headlines.
The one positive trial
The most-cited human NMN result is a 2021 trial published in Science: 25 postmenopausal women with prediabetes, overweight or obese, given 250 mg NMN daily for ten weeks. It reported increased muscle insulin sensitivity.3
Two things belong beside it. First, the size: twenty-five participants in a narrowly defined population is a starting point, not a conclusion — and its findings sit inside the pooled analyses above, which came out null overall.
Second, the result was formally contested. Science published a technical comment challenging the analysis, alongside the authors' response.4 A published dispute doesn't mean the finding is wrong; it means the interpretation was not settled by publication, which is exactly the context that gets stripped away when a single trial is cited as proof.
Three claims, three different grades
NMN is a good illustration of why grades attach to specific claims rather than to compounds. Ask three different questions and you get three different answers.
Read down that list and the picture is coherent: NMN reliably does the biochemical thing it is supposed to do, has not been shown to produce a downstream health benefit, and has never been tested against the outcome it is actually sold for.
Twelve weeks against a lifetime
The trials in these reviews ran a mean of about 9.6 weeks, with a range of four to twelve.2
Aging is measured in decades. A twelve-week trial cannot detect a change in the rate of aging even in principle — not because the researchers did anything wrong, but because the question is longer than the study. Any claim that NMN slows aging in humans is currently an extrapolation from rodent lifespan work and a biochemical mechanism, not a finding from human data.
That extrapolation may eventually prove right. It has not yet been tested.
Safety and unknowns
-
Adverse events reported
Across the randomized trials reviewed, NMN was well tolerated with no serious adverse effects reported.2 A separate review found no clear increase in adverse events or liver biochemistry abnormalities at the doses studied.
-
Longest human exposure studied
Approximately 12 weeks. Mean follow-up across ten trials was 9.6 weeks, range 4–12 weeks, at doses of 150–1,200 mg/day.2 Nothing published characterises exposure beyond about three months.
-
Known interactions and at-risk groups
Not characterised. Trial populations were predominantly middle-aged and older adults without diabetes; the reviews note this limits generalisability.12
-
Regulatory status
Lawful in US dietary supplements. In letters dated 29 September 2025 the FDA concluded NMN is not excluded from the definition of a dietary supplement, reversing its earlier position that NMN was precluded because it had been authorised for investigation as a new drug. The reversal rested on the "race to market" provision — evidence that NMN was marketed as a supplement in the US before the drug authorisation date.5
-
What has not been characterized
Safety beyond roughly three months. Any effect on lifespan, healthspan, or disease incidence. Long-term consequences of sustained NAD+ elevation. Effects in younger adults, and in people with diabetes or significant comorbidity. No trial cited here speaks to the identity or purity of any particular commercial product.
How this was graded
Evidence strength — Moderate, criteria checked
Verdict is Not supported because the pooled analyses found no significant benefit on the clinical outcomes measured. Note what this does not say: it does not say NMN fails to raise NAD+ — it does, and that claim is graded Supported above. It says the downstream benefit has not been demonstrated.
Bottom line
NMN does the biochemistry it promises. Blood NAD+ goes up in most trials that measure it. That part is real.
What roughly a dozen randomized trials in several hundred people have not found is any consistent downstream benefit — not to glucose, not to lipids, not to strength or walking speed. And the outcome NMN is actually marketed for, slowing aging, has never been measured in a human trial, because the longest studies run about twelve weeks against a process that takes decades.
Raising a number in a blood test is not the same as getting healthier. Everything about this compound turns on that distinction.
Sources
- Chen F, Zhou D, Kong APS, et al. Effects of nicotinamide mononucleotide on glucose and lipid metabolism in adults: a systematic review and meta-analysis of randomised controlled trials. Current Diabetes Reports. 2024;25(1):4. PMC11557618
- Wen J, Syed B, Kim S, et al. Improved physical performance parameters in patients taking nicotinamide mononucleotide (NMN): a systematic review of randomized control trials. Cureus. 2024;16(8):e65961. PMC11365583
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. PMID 33888596
- Technical comment and authors' response on Yoshino et al. Science. 2021. doi:10.1126/science.abj1696 — cited to establish that the finding was formally contested in the literature.
- Venable LLP. FDA declares nicotinamide mononucleotide is a dietary supplement. October 2025, reporting FDA letters dated 29 September 2025. venable.com — legal analysis cited for regulatory status; FDA's letters were not independently retrieved.
